

In one aspect, the present disclosure refers to the use of a MASP-2 inhibitory monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6 in the manufacture of a medicament for preventing, treating, reverting and/or  
5 delaying angiogenesis in a mammalian subject suffering from an angiogenesis-dependent cancer or an angiogenesis-dependent benign tumor. In another example, the present disclosure refers to the use of a MASP-2 inhibitory agent in the manufacture of a medicament for treating a subject suffering from an ocular angiogenic disease or condition selected from the group consisting of AMD, uveitis, ocular melanoma, corneal  
10 neovascularization, primary pterygium, HSV stromal keratitis, HSV-1-induced corneal lymphangiogenesis, proliferative diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, corneal graft rejection, neovascular glaucoma, and rubeosis. In still another example, the present disclosure refers to the use of a MASP-2 inhibitory agent in the manufacture of a medicament for inhibiting tumor angiogenesis in a subject with  
15 cancer. Also described herein are methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising

administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some examples of these aspects of the disclosure, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof. In further examples, the MASP-2 antibody has reduced effector function. In some examples, the MASP-2 inhibitory agent is a MASP-2 inhibitory peptide or a non-peptide MASP-2 inhibitor.

In another example, provided herein are compositions for inhibiting the adverse effects of angiogenesis, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. Methods are also provided for manufacturing a medicament for use in inhibiting the adverse effects of angiogenesis in living subjects in need thereof, comprising a therapeutically effective amount of a MASP-2 inhibitory agent in a pharmaceutical carrier. Methods are also provided for manufacturing medicaments for use in inhibiting angiogenesis for treatment of each of the conditions, diseases and disorders described herein below.

The methods, compositions and medicaments described herein are useful for inhibiting the adverse effects of angiogenesis *in vivo* in mammalian subjects, including humans suffering from an acute or chronic pathological condition or injury as further described herein.

In another example described herein, methods are provided for inhibiting angiogenesis in a mammalian subject suffering from an angiogenesis-dependent disease or condition comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some examples, the angiogenesis-dependent disease or condition is an angiogenesis-dependent cancer, such as, for example, an angiogenesis-dependent cancer selected from the group consisting of solid tumor(s), blood borne tumors, high-risk carcinoid tumors, and tumor metastases. In some examples, the angiogenesis-dependent disease or condition is an angiogenesis-dependent benign tumor, such as, for example, an angiogenesis-dependent benign tumor selected from the group consisting of hemangiomas, acoustic neuromas, neurofibromas, trachomas, carcinoid tumors, and pyogenic granulomas. In some

## CLAIMS

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. Use of a MASP-2 inhibitory monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6 in the manufacture of a medicament for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from an angiogenesis-dependent cancer or an angiogenesis-dependent benign tumor.
2. The use of Claim 1, wherein the subject is suffering from an angiogenesis-dependent cancer selected from the group consisting of: solid tumor(s), blood borne tumors, high-risk carcinoid tumors, and tumor metastases.
3. The use of Claim 2, wherein the subject is suffering from one or more solid tumors.
4. The use of Claim 3, wherein the subject is suffering from or at risk for tumor metastases.
5. The use of Claim 1, wherein the subject is suffering from an angiogenesis-dependent benign tumor(s) selected from the group consisting of hemangiomas, acoustic neuromas, neurofibromas, trachomas, carcinoid tumors, and pyogenic granulomas.
6. The use of Claim 1, wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody.
7. The use of Claim 1, wherein the composition is for subcutaneous administration, intraperitoneal administration, intra-muscular administration, intra-arterial administration, intravenous administration, or as an inhalant.